| Literature DB >> 30037171 |
Jaeyoung Chun1, Jong Pil Im1, Ji Won Kim2, Kook Lae Lee2, Chang Hwan Choi3, Hyunsoo Kim4, Jae Hee Cheon5, Byong Duk Ye6, Young-Ho Kim7, You Sun Kim8, Yoon Tae Jeen9, Dong Soo Han10, Won Ho Kim5, Joo Sung Kim1.
Abstract
Background/Aims: The disease course and factors associated with poor prognosis in Korean patients with Crohn's disease (CD) have not been fully determined. The aim of this study was to explore potential associations between the clinical characteristics and long-term outcomes of CD and perianal fistulas in a Korean population.Entities:
Keywords: Anal fistula; Crohn disease; Prognosis
Mesh:
Year: 2018 PMID: 30037171 PMCID: PMC6143449 DOI: 10.5009/gnl18157
Source DB: PubMed Journal: Gut Liver ISSN: 1976-2283 Impact factor: 4.519
Fig. 1Flowchart for patient selection.
CD, Crohn’s disease.
Baseline Characteristics
| Characteristics | Without perianal fistulas | With perianal fistulas | p-value |
|---|---|---|---|
| No. of patients | 728 (61.0) | 465 (39.0) | - |
| Age at diagnosis, yr | 29.0±13.3 | 23.6±8.4 | <0.001 |
| Age at diagnosis (Montreal classification) | <0.001 | ||
| ≤16 yr (A1) | 76 (10.4) | 69 (14.8) | |
| 17–40 yr (A2) | 521 (71.6) | 377 (81.1) | |
| ≥41 yr (A3) | 131 (18.0) | 19 (4.1) | |
| Male sex | 497 (68.3) | 343 (73.8) | 0.043 |
| Hospital where patients were diagnosed with CD | <0.001 | ||
| Primary care clinic | 111 (15.4) | 131 (28.3) | |
| Referral hospital | 602 (83.7) | 332 (71.7) | |
| Overseas | 6 (0.8) | 0 | |
| Anti-tuberculosis medication | 171 (23.7) | 109 (23.6) | 0.985 |
| Family history of IBD | 16 (2.3) | 14 (3.1) | 0.382 |
| Location of disease (Montreal classification) | <0.001 | ||
| Ileum (L1) | 203 (27.9) | 73 (15.7) | |
| Colon (L2) | 107 (14.7) | 68 (14.6) | |
| Ileocolon (L3) | 409 (56.2) | 324 (69.7) | |
| Concomitant UGI disease (L4) | 185 (25.4) | 96 (20.6) | 0.058 |
Data are presented as number (%) or mean±SD.
CD, Crohn’s disease; IBD, inflammatory bowel disease; UGI, upper gastrointestinal.
Age at diagnosis and disease location was determined according to the revised Montreal classification.
Perianal Fistulas and Treatment for Crohn’s Disease
| Without perianal fistulas (n=728) | With perianal fistulas (n=465) | p-value | |
|---|---|---|---|
| 5-ASA | 691 (97.3) | 451 (99.1) | 0.031 |
| Antibiotics | 364 (52.4) | 327 (72.7) | <0.001 |
| Topical corticosteroids | 99 (13.8) | 63 (13.9) | 0.980 |
| Systemic corticosteroids | 436 (60.3) | 312 (68.1) | 0.007 |
| Azathioprine/6-mercaptopurine | 502 (69.0) | 378 (81.3) | <0.001 |
| Methotrexate | 12 (1.7) | 9 (1.9) | 0.713 |
| TNF-α antagonist | 179 (24.6) | 157 (33.8) | 0.001 |
| Infliximab | 155 (21.3) | 145 (31.2) | <0.001 |
| Adalimumab | 48 (6.6) | 28 (6.0) | 0.693 |
Data are presented as number (%).
5-ASA, 5-aminosalicylic acid; TNF-α, tumor necrosis factor-α.
Fig. 2Kaplan-Meier curves for clinical outcomes of Crohn’s disease (CD). (A) Cumulative risks of complicated nonperianal fistulas, (B) intra-abdominal abscess formation, (C) complicated strictures, and (D) CD-related surgery.
Perianal Fistulas and Clinical Outcomes of Crohn’s Disease
| Without perianal fistulas (n=728) | With perianal fistulas (n=465) | p-value | |
|---|---|---|---|
| CD-related complications | |||
| Nonperianal fistulas | 104 (14.3) | 88 (18.9) | 0.034 |
| Strictures | 198 (27.2) | 140 (30.1) | 0.564 |
| Intra-abdominal abscess | 86 (11.8) | 77 (16.6) | 0.020 |
| CD-related surgery | 202 (27.7) | 122 (26.2) | 0.202 |
Data are presented as number (%).
CD, Crohn’s disease.
Fig. 3Kaplan-Meier curves for clinical outcomes of Crohn’s disease (CD) according to the presence of perianal fistula. (A) Cumulative risks of complicated nonperianal fistulas, (B) intra-abdominal abscess formation, (C) complicated strictures, and (D) CD-related surgery.
Predictors of Nonperianal Fistula in the Study Population
| Variable | Univariate analysis (log-rank test) | Multivariate analysis (Cox proportional hazard models) | |||
|---|---|---|---|---|---|
|
|
| ||||
| % | p-value | Adjusted HR | 95% CI | p-value | |
| Age at diagnosis (Montreal classification) | 0.271 | - | - | - | |
| ≤16 yr (A1) | 17.2 | ||||
| 17–40 yr (A2) | 16.8 | ||||
| ≥41 yr (A3) | 10.7 | ||||
| Sex | 0.046 | ||||
| Male | 14.4 | 1 (reference) | |||
| Female | 20.1 | 1.341 | 1.003–1.793 | 0.048 | |
| Hospital where patients were diagnosed with CD | 0.068 | ||||
| Primary care clinic | 11.2 | 1 (reference) | |||
| Referral hospital | 17.3 | 1.852 | 1.227–2.796 | 0.003 | |
| Overseas | 16.7 | 4.393 | 0.214–19.027 | 0.489 | |
| Anti-tuberculosis medication | 0.927 | - | - | - | |
| No | 15.7 | ||||
| Yes | 17.1 | ||||
| Family history of IBD | 0.169 | - | - | - | |
| No | 16.4 | ||||
| Yes | 6.7 | ||||
| Location of disease (Montreal classification) | 0.011 | ||||
| Ileum (L1) | 14.1 | 1 (reference) | |||
| Colon (L2) | 8.6 | 0.627 | 0.353–1.113 | 0.111 | |
| Ileocolon (L3) | 18.7 | 1.263 | 0.887–1.798 | 0.195 | |
| Concomitant UGI disease (L4) | 0.001 | ||||
| No | 14.0 | 1 (reference) | |||
| Yes | 22.7 | 1.655 | 1.222–2.241 | 0.001 | |
| Perianal fistula | 0.034 | ||||
| No | 14.3 | 1 (reference) | |||
| Yes | 18.9 | 1.430 | 1.072–1.908 | 0.015 | |
HR, hazard ratio; CI, confidence interval; CD, Crohn’s disease; IBD, inflammatory bowel disease; UGI, upper gastrointestinal.
Age at diagnosis and disease location was determined according to the revised Montreal classification.
Predictors of Intra-abdominal Abscess in the Study Population
| Variable | Univariate analysis (log-rank test) | Multivariate analysis (Cox proportional hazard models) | |||
|---|---|---|---|---|---|
|
|
| ||||
| % | p-value | Adjusted HR | 95% CI | p-value | |
| Age at diagnosis (Montreal classification) | 0.020 | ||||
| ≤16 yr (A1) | 9.0 | 1 (reference) | |||
| 17–40 yr (A2) | 15.4 | 1.816 | 0.989–3.643 | 0.076 | |
| ≥41 yr (A3) | 8.0 | 1.153 | 0.544–2.444 | 0.710 | |
| Sex | 0.338 | - | - | - | |
| Male | 14.0 | ||||
| Female | 12.7 | ||||
| Hospital where patients were diagnosed with CD | 0.236 | - | - | - | |
| Primary care clinic | 10.7 | ||||
| Referral hospital | 14.0 | ||||
| Overseas | 33.3 | ||||
| Anti-tuberculosis medication | 0.807 | - | - | - | |
| No | 13.4 | ||||
| Yes | 14.3 | ||||
| Family history of IBD | 0.097 | - | - | -- | |
| No | 13.9 | ||||
| Yes | 3.3 | ||||
| Location of disease (Montreal classification) | 0.099 | - | - | - | |
| Ileum (L1) | 12.7 | ||||
| Colon (L2) | 8.6 | ||||
| Ileocolon (L3) | 15.1 | ||||
| Concomitant UGI disease (L4) | 0.028 | ||||
| No | 12.4 | 1 (reference) | |||
| Yes | 17.8 | 1.510 | 1.094–2.082 | 0.012 | |
| Perianal Fistula | 0.020 | ||||
| No | 11.8 | 1 (reference) | |||
| Yes | 16.6 | 1.292 | 1.005–1.748 | 0.048 | |
HR, hazard ratio; CI, confidence interval; CD, Crohn’s disease; IBD, inflammatory bowel disease; UGI, upper gastrointestinal.
Age at diagnosis and disease location was determined according to the revised Montreal classification.